Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Prime Medicine Inc. (PRME:NASDAQ), powered by AI.
Prime Medicine Inc. is currently trading at $2.87. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Prime Medicine Inc. on Alpha Lenz.
Prime Medicine Inc.'s P/E ratio is -2.1.
“Prime Medicine Inc. trades at a P/E of -2.1 (undervalued) with modest ROE of -146.8%.”
Ask for details →Prime Medicine Inc. is a pioneering biotechnology company focused on the development of prime editing, a novel gene editing technology. This advanced approach aims to precisely edit the human genome by correcting genetic mutations at the DNA level without introducing double-strand breaks. Unlike traditional CRISPR methods, prime editing offers a higher level of accuracy and fewer unintended consequences, representing a transformative step in the treatment of genetic disorders. Prime Medicine operates within the cutting-edge sectors of biotechnology and healthcare, targeting therapeutic solutions for various genetic diseases that have remained challenging to treat with existing technologies. By leveraging prime editing, Prime Medicine seeks to address a wide spectrum of conditions, potentially revolutionizing personalized medicine and genomic interventions. The company's expertise in genetic editing plays a crucial role in advancing medical science and holds significant promise for improving patient outcomes and extending the frontiers of gene therapy.
“Prime Medicine Inc. trades at a P/E of -2.1 (undervalued) with modest ROE of -146.8%.”
Ask for details →Prime Medicine Inc. (ticker: PRME) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 214 employees. Market cap is $427M.
The current price is $2.87 with a P/E ratio of -2.12x and P/B of 3.53x.
ROE is -146.81% and operating margin is -4498.06%. Annual revenue is $5M.